legal · go-v.org

Legal · US

225,069 document(s) from the ingested source(s); showing 100.

page 12 of 2251 · 225,069 documents · previous next

(Item 305) Quantitative and qualitative disclosures about market risk.

CFR · 2024-01-01 · US · Title 17

(a) (i)(A)( ( ( ( (B) Registrants shall provide a description of the contents of the table and any related assumptions necessary to understand the disclosures required under paragraph (a)(1)(i)(A) of this Item 305; or (ii)(A) Sensitivity analysis disclosures that express the potential loss in future earnings, fair values, or cash flows of market risk sensitive instruments resulting from one or more selected hypothetical changes in interest rates, foreign currency exchange rates, commodity prices, and other relevant market rates or prices over a selected period of time. The magnitude of selected hypothetical changes in rates or prices may differ among and within market risk exposure categories; and (B) Registrants shall provide a description of the model, assumptions, and parameters, which are necessary to (iii)(A) Value at risk disclosures that express the potential loss in future earnings, fair values, or cash flows of market risk sensitive instruments over a selected period of time, with a selected likelihood of occurrence, from changes in interest rates, foreign currency exchange rates, commodity prices, and other relevant market rates or prices; (B)( ( ( ( ( (C) Registrants shall provide a description of the model, assumptions, and parameters, which are necessary to understand the disclosures required under paragraphs (a)(1)(iii)(A) and (B) of this Item 305. (2) Registrants shall discuss material limitations that cause the information required under paragraph (a)(1) of th

official document · source cfr-2024

(Item 307) Disclosure controls and procedures.

CFR · 2024-01-01 · US · Title 17

Disclose the conclusions of the registrant's principal executive and principal financial officers, or persons performing similar functions, regarding the effectiveness of the registrant's disclosure controls and procedures (as defined in § 240.13a-15(e) or § 240.15d-15(e) of this chapter) as of the end of the period covered by the report, based on the evaluation of these controls and procedures required by paragraph (b) of § 240.13a-15 or § 240.15d-15 of this chapter.

official document · source cfr-2024

(Item 308) Internal control over financial reporting.

CFR · 2024-01-01 · US · Title 17

(a) (1) A statement of management's responsibility for establishing and maintaining adequate internal control over financial reporting for the registrant; (2) A statement identifying the framework used by management to evaluate the effectiveness of the registrant's internal control over financial reporting as required by paragraph (c) of § 240.13a-15 or § 240.15d-15 of this chapter; (3) Management's assessment of the effectiveness of the registrant's internal control over financial reporting as of the end of the registrant's most recent fiscal year, including a statement as to whether or not internal control over financial reporting is effective. This discussion must include disclosure of any material weakness in the registrant's internal control over financial reporting identified by management. Management is not permitted to conclude that the registrant's internal control over financial reporting is effective if there are one or more material weaknesses in the registrant's internal control over financial reporting; and (4) If the registrant is an accelerated filer or a large accelerated filer (as defined in § 240.12b-2 of this chapter), or otherwise includes in its annual report a registered public accounting firm's attestation report on internal control over financial reporting, a statement that the registered public accounting firm that audited the financial statements included in the annual report containing the disclosure required by this Item has issued an attestation

official document · source cfr-2024

(Item 401) Directors, executive officers, promoters and control persons.

CFR · 2024-01-01 · US · Title 17

(a) (b) (c) (d) (e) (2) (f) (1) A petition under the Federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing; (2) Such person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) Such person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities: (i) Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; (ii) Engaging

official document · source cfr-2024

(Item 402) Executive compensation.

CFR · 2024-01-01 · US · Title 17

(a) (2) (3) (i) All individuals serving as the registrant's principal executive officer or acting in a similar capacity during the last completed fiscal year (“PEO”), regardless of compensation level; (ii) All individuals serving as the registrant's principal financial officer or acting in a similar capacity during the last completed fiscal year (“PFO”), regardless of compensation level; (iii) The registrant's three most highly compensated executive officers other than the PEO and PFO who were serving as executive officers at the end of the last completed fiscal year; and (iv) Up to two additional individuals for whom disclosure would have been provided pursuant to paragraph (a)(3)(iii) of this Item but for the fact that the individual was not serving as an executive officer of the registrant at the end of the last completed fiscal year. (4) (5) (6) (i) The term (ii) The term (iii) The term (iv) The terms (v) (b) (i) The objectives of the registrant's compensation programs; (ii) What the compensation program is designed to reward; (iii) Each element of compensation; (iv) Why the registrant chooses to pay each element; (v) How the registrant determines the amount (and, where applicable, the formula) for each element to pay; (vi) How each compensation element and the registrant's decisions regarding that element fit into the registrant's overall compensation objectives and affect decisions regarding other elements; and (vii) Whether and, if so, how the registrant has considered

official document · source cfr-2024

(Item 403) Security ownership of certain beneficial owners and management.

CFR · 2024-01-01 · US · Title 17

(a) (b) (c)

official document · source cfr-2024

(Item 404) Transactions with related persons, promoters and certain control persons.

CFR · 2024-01-01 · US · Title 17

(a) (1) The name of the related person and the basis on which the person is a related person. (2) The related person's interest in the transaction with the registrant, including the related person's position(s) or relationship(s) with, or ownership in, a firm, corporation, or other entity that is a party to, or has an interest in, the transaction. (3) The approximate dollar value of the amount involved in the transaction. (4) The approximate dollar value of the amount of the related person's interest in the transaction, which shall be computed without regard to the amount of profit or loss. (5) In the case of indebtedness, disclosure of the amount involved in the transaction shall include the largest aggregate amount of principal outstanding during the period for which disclosure is provided, the amount thereof outstanding as of the latest practicable date, the amount of principal paid during the periods for which disclosure is provided, the amount of interest paid during the period for which disclosure is provided, and the rate or amount of interest payable on the indebtedness. (6) Any other information regarding the transaction or the related person in the context of the transaction that is material to investors in light of the circumstances of the particular transaction. (b) (i) The types of transactions that are covered by such policies and procedures; (ii) The standards to be applied pursuant to such policies and procedures; (iii) The persons or groups of persons on the

official document · source cfr-2024

(Item 405) Compliance with Section 16(a) of the Exchange Act.

CFR · 2024-01-01 · US · Title 17

(a) (1) Under the caption “Delinquent Section 16(a) Reports,” identify each person who, at any time during the fiscal year, was a director, officer, beneficial owner of more than ten percent of any class of equity securities of the registrant registered pursuant to Section 12 of the Exchange Act, or any other person subject to Section 16 of the Exchange Act with respect to the registrant because of the requirements of Section 30 of the Investment Company Act (“reporting person”) that failed to file on a timely basis reports required by Section 16(a) of the Exchange Act during the most recent fiscal year or prior fiscal years. (2) For each such person, set forth the number of late reports, the number of transactions that were not reported on a timely basis, and any known failure to file a required form. A known failure to file would include, but not be limited to, a failure to file a Form 3, which is required of all reporting persons, and a failure to file a Form 5 in the absence of the written representation referred to in paragraph (b)(3) of (b) (1) A review of Forms 3 and 4 (17 CFR 249.103 and 249.104) and amendments thereto filed electronically with the Commission during the registrant's most recent fiscal year; (2) A review of Forms 5 (17 CFR 249.105) and amendments thereto filed electronically with the Commission with respect to the registrant's most recent fiscal year; and (3) Any written representation from the reporting person that no Form 5 is required. The registran

official document · source cfr-2024

(Item 406) Code of ethics.

CFR · 2024-01-01 · US · Title 17

(a) Disclose whether the registrant has adopted a code of ethics that applies to the registrant's principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. If the registrant has not adopted such a code of ethics, explain why it has not done so. (b) For purposes of this Item 406, the term (1) Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (2) Full, fair, accurate, timely, and understandable disclosure in reports and documents that a registrant files with, or submits to, the Commission and in other public communications made by the registrant; (3) Compliance with applicable governmental laws, rules and regulations; (4) The prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and (5) Accountability for adherence to the code. (c) The registrant must: (1) File with the Commission a copy of its code of ethics that applies to the registrant's principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, as an exhibit to its annual report; (2) Post the text of such code of ethics on its Internet website and disclose, in its annual report, its Internet address and the fact that it has posted such code of ethics on its Internet Web site; or (3) Undertake in its

official document · source cfr-2024

(Item 407) Corporate governance.

CFR · 2024-01-01 · US · Title 17

(a) (1) In determining whether or not the director or nominee for director is independent for the purposes of paragraph (a) of this Item, the registrant shall use the applicable definition of independence, as follows: (i) If the registrant is a listed issuer whose securities are listed on a national securities exchange or in an inter-dealer quotation system which has requirements that a majority of the board of directors be independent, the registrant's definition of independence that it uses for determining if a majority of the board of directors is independent in compliance with the listing standards applicable to the registrant. When determining whether the members of a committee of the board of directors are independent, the registrant's definition of independence that it uses for determining if the members of that specific committee are independent in compliance with the independence standards applicable for the members of the specific committee in the listing standards of the national securities exchange or inter-dealer quotation system that the registrant uses for determining if a majority of the board of directors are independent. If the registrant does not have independence standards for a committee, the independence standards for that specific committee in the listing standards of the national securities exchange or inter-dealer quotation system that the registrant uses for determining if a majority of the board of directors are independent. (ii) If the registrant i

official document · source cfr-2024

(Item 408) Insider trading arrangements and policies.

CFR · 2024-01-01 · US · Title 17

(a)(1) Disclose whether, during the registrant's last fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report), any director or officer (as defined in § 240.16a-1(f) of this chapter) adopted or terminated: (i) Any contract, instruction or written plan for the purchase or sale of securities of the registrant intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (§ 240.10b5-1(c) of this chapter) (a “Rule 10b5-1 trading arrangement”); and/or (ii) Any “non-Rule 10b5-1 trading arrangement” as defined in paragraph (c) of this section. (2) Identify whether the trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c), and provide a description of the material terms, other than terms with respect to the price at which the individual executing the Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement is authorized to trade, such as: (A) The name and title of the director or officer; (B) The date on which the director or officer adopted or terminated the trading arrangement; (C) The duration of the trading arrangement; and (D) The aggregate number of securities to be purchased or sold pursuant to the trading arrangement. (3) The disclosure provided pursuant to paragraphs (a)(1) and (2) of this section must be provided in an Interactive Data File as required by 17 CFR 232.405 (Rule 405 of Regulation S-T) in accordance with the EDGAR Filer Manual. (b)(1) Disclose whether the registrant has adopt

official document · source cfr-2024

(Item 501) Forepart of Registration Statement and Outside Front Cover Page of Prospectus.

CFR · 2024-01-01 · US · Title 17

The registrant must furnish the following information in plain English. See § 230.421(d) of Regulation C of this chapter. (a) (b) (1) (2) (3) (4) (5) (6) (7) (8) (ii) If the offering is not made on a firm commitment basis, a brief description of the underwriting arrangements. You may use any clear, concise, and accurate description of the underwriting arrangements. You may use the following descriptions of underwriting arrangements where appropriate: (iii) If you offer the securities on a best efforts or best efforts minimum/maximum basis, the date the offering will end, any minimum purchase requirements, and any arrangements to place the funds in an escrow, trust, or similar account. If you have not made any of these arrangements, state this fact and describe the effect on investors; (9) (10) (A) The information in the prospectus will be amended or completed; (B) A registration statement relating to these securities has been filed with the Securities and Exchange Commission; (C) The securities may not be sold until the registration statement becomes effective; and (D) The prospectus is not an offer to sell the securities, and it is not soliciting an offer to buy the securities, in any state where offers or sales are not permitted. (ii) The legend called for by paragraph (b)(10)(i) of this Item may be in the following or other clear, plain language: The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration s

official document · source cfr-2024

(Item 502) Inside front and outside back cover pages of prospectus.

CFR · 2024-01-01 · US · Title 17

The registrant must furnish this information in plain English. See § 230.421(d) of Regulation C of this chapter. (a) (b)

official document · source cfr-2024

(Item 503) Prospectus summary.

CFR · 2024-01-01 · US · Title 17

The registrant must furnish this information in plain English. See § 230.421(d) of Regulation C of this chapter. (a) (b) (c) [Reserved]

official document · source cfr-2024

(Item 504) Use of proceeds.

CFR · 2024-01-01 · US · Title 17

State the principal purposes for which the net proceeds to the registrant from the securities to be offered are intended to be used and the approximate amount intended to be used for each such purpose. Where registrant has no current specific plan for the proceeds, or a significant portion thereof, the registrant shall so state and discuss the principal reasons for the offering.

official document · source cfr-2024

(Item 505) Determination of offering price.

CFR · 2024-01-01 · US · Title 17

(a) (b)

official document · source cfr-2024

(Item 506) Dilution.

CFR · 2024-01-01 · US · Title 17

Where common equity securities are being registered and there is substantial disparity between the public offering price and the effective cash cost to officers, directors, promoters and affiliated persons of common equity acquired by them in transactions during the past five years, or which they have the right to acquire, and the registrant is not subject to the reporting requirements of section 13(a) or 15(d) of the Exchange Act immediately prior to filing of the registration statement, there shall be included a comparison of the public contribution under the proposed public offering and the effective cash contribution of such persons. In such cases, and in other instances where common equity securities are being registered by a registrant that has had losses in each of its last three fiscal (a) The net tangible book value per share before and after the distribution; (b) The amount of the increase in such net tangible book value per share attributable to the cash payments made by purchasers of the shares being offered; and (c) The amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.

official document · source cfr-2024

(Item 507) Selling security holders.

CFR · 2024-01-01 · US · Title 17

If any of the securities to be registered are to be offered for the account of security holders, name each such security holder, indicate the nature of any position, office, or other material relationship which the selling security holder has had within the past three years with the registrant or any of its predecessors or affiliates, and state the amount of securities of the class owned by such security holder prior to the offering, the amount to be offered for the security holder's account, the amount and (if one percent or more) the percentage of the class to be owned by such security holder after completion of the offering.

official document · source cfr-2024

(Item 508) Plan of distribution.

CFR · 2024-01-01 · US · Title 17

(a) (b) (c) (1) If any securities are to be offered pursuant to a dividend or interest reinvestment plan the terms of which provide for the purchase of some securities on the market, state whether the registrant or the participant pays fees, commissions, and expenses incurred in connection with the plan. If the participant will pay such fees, commissions and expenses, state the anticipated cost to participants by transaction or other convenient reference. (2) If the securities are to be offered through the selling efforts of brokers or dealers, describe the plan of distribution and the terms of any agreement, arrangement, or understanding entered into with broker(s) or dealer(s) prior to the effective date of the registration statement, including volume limitations on sales, parties to the agreement and the conditions under (3) If any of the securities being registered are to be offered otherwise than for cash, state briefly the general purposes of the distribution, the basis upon which the securities are to be offered, the amount of compensation and other expenses of distribution, and by whom they are to be borne. If the distribution is to be made pursuant to a plan of acquisition, reorganization, readjustment or succession, describe briefly the general effect of the plan and state when it became or is to become operative. As to any material amount of assets to be acquired under the plan, furnish information corresponding to that required by Instruction 5 of Item 504 of Regu

official document · source cfr-2024

(Item 509) Interests of named experts and counsel.

CFR · 2024-01-01 · US · Title 17

If (a) any expert named in the registration statement as having prepared or certified any part thereof (or is named as having prepared or certified a report or valuation for use in connection with the registration statement), or (b) counsel for the registrant, underwriters or selling security holders named in the prospectus as having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of such securities, was employed for such purpose on a contingent basis, or at the time of such preparation, certification or opinion or at any time thereafter, through the date of effectiveness of the registration statement or that part of the registration statement to which such preparation, certification or opinion relates, had, or is to receive in connection with the offering, a substantial interest, direct or indirect, in the registrant or any of its parents or subsidiaries or was connected with the registrant or any of its parents or subsidiaries as a promoter, managing underwriter (or any principal underwriter, if there are no managing underwriters) voting trustee, director, officer, or employee, furnish a brief statement of the nature of such contingent basis, interest, or connection.

official document · source cfr-2024

(Item 510) Disclosure of Commission position on indemnification for Securities Act liabilities.

CFR · 2024-01-01 · US · Title 17

In addition to the disclosure prescribed by Item 702 of Regulation S-K (§ 229.702), if the undertaking required by paragraph (h) of Item 512 of Regulation S-K (§ 229.512) is not required to be included in the registration statement because acceleration of the effective date of the registration statement is not being requested, and if waivers have not been obtained comparable to those specified in paragraph (h), a brief description of the indemnification provisions relating to directors, officers and controlling persons of the registrant against liability arising under the Securities Act (including any provision of the underwriting agreement which relates to indemnification of the underwriter or its controlling persons by the registrant against such liabilities where a director, officer or controlling person of the registrant is such an underwriter or controlling person thereof or a member of any firm which is such an underwriter) shall be included in the prospectus, together with a statement in substantially the following form:

official document · source cfr-2024

(Item 511) Other expenses of issuance and distribution.

CFR · 2024-01-01 · US · Title 17

Furnish a reasonably itemized statement of all expenses in connection with the issuance and distribution of the securities to be registered, other than underwriting discounts and commissions. If any of the securities to be registered are to be offered for the account of security holders, indicate the portion of such expenses to be borne by such security holder.

official document · source cfr-2024

(Item 512) Undertakings.

CFR · 2024-01-01 · US · Title 17

Include each of the following undertakings that is applicable to the offering being registered. (a) The undersigned registrant hereby undertakes: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933; (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (§ 230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement. (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change t

official document · source cfr-2024

(Item 601) Exhibits.

CFR · 2024-01-01 · US · Title 17

(a) * * * (b) * * * (27)

official document · source cfr-2024

(Item 701) Recent sales of unregistered securities; use of proceeds from registered securities.

CFR · 2024-01-01 · US · Title 17

Furnish the following information as to all securities of the registrant sold by the registrant within the past three years which were not registered under the Securities Act. Include sales of reacquired securities, as well as new issues, securities issued in exchange for property, services, or other securities, and new securities resulting from the modification of outstanding securities. (a) (b) (c) (d) (e) (f) (1) The effective date of the Securities Act registration statement for which the use of proceeds information is being disclosed and the Commission file number assigned to the registration statement; (2) If the offering has commenced, the offering date, and if the offering has (3) If the offering terminated before any securities were sold, an explanation for such termination; and (4) If the offering did not terminate before any securities were sold, disclose: (i) Whether the offering has terminated and, if so, whether it terminated before the sale of all securities registered; (ii) The name(s) of the managing underwriter(s), if any; (iii) The title of each class of securities registered and, where a class of convertible securities is being registered, the title of any class of securities into which such securities may be converted; (iv) For each class of securities (other than a class of securities into which a class of convertible securities registered may be converted without additional payment to the issuer) the following information, provided for both the account

official document · source cfr-2024

(Item 702) Indemnification of directors and officers.

CFR · 2024-01-01 · US · Title 17

State the general effect of any statute, charter provisions, by-laws, contract or other arrangements under which any controlling persons, director or officer of the registrant is insured or

official document · source cfr-2024

(Item 703) Purchases of equity securities by the issuer and affiliated purchasers.

CFR · 2024-01-01 · US · Title 17

(a) Disclose the specified information in narrative form with respect to the issuer's repurchases of equity securities disclosed pursuant to § 229.601(b)(26) (Item 601(b)(26) of Regulation S-K) and refer to the particular repurchases in the table in Item 601(b)(26) of Regulation S-K that correspond to the different parts of the narrative, if applicable: (1) The objectives or rationales for each repurchase plan or program and the process or criteria used to determine the amount of repurchases. (2) The number of shares (or units) purchased other than through a publicly announced plan or program, and the nature of the transaction (e.g., whether the purchases were made in open-market transactions, tender offers, in satisfaction of the issuer's obligations upon exercise of outstanding put options issued by the issuer, or other transactions). (3) For publicly announced repurchase plans or programs: (i) The date each plan or program was announced; (ii) The dollar amount (or share or unit amount) approved; (iii) The expiration date (if any) of each plan or program; (iv) Each plan or program that has expired during the period covered by the table in Item 601(b)(26) of Regulation S-K; and (v) Each plan or program the issuer has determined to terminate prior to expiration, or under which the issuer does not intend to make further purchases. (4) Any policies and procedures relating to purchases and sales of the issuer's securities by its officers and directors during a repurchase program

official document · source cfr-2024

(Item 901) Definitions.

CFR · 2024-01-01 · US · Title 17

For the purposes of this subpart 229.900: (a) (b)(1) (i) Finite-life limited partnership; or (ii) Other finite-life entity. (2)(i) Except as provided in paragraph (b)(2)(ii) of this Item (§ 229.901(b)(2)(ii)), a limited partnership or other entity is “finite-life” if: (A) It operates as a conduit vehicle for investors to participate in the ownership of assets for a limited period of time; and (B) It has as a policy or purpose distributing to investors proceeds from the sale, financing or refinancing of assets or cash from operations, rather than reinvesting such proceeds or cash in the business (whether for the term of the entity or after an initial period of time following commencement of operations). (ii) A real estate investment trust as defined in I.R.C. section 856 is not (3) (c)(1) Except as provided in paragraph (c)(2) or (c)(3) of this Item, (§ 229.901(c)(2) or (c)(3)) (2) Notwithstanding paragraph (c)(1) of this Item, (§ 229.901(c)(1)) (i) A transaction wherein the interests of all of the investors in each of the partnerships are repurchased, recalled, or exchanged in accordance with the terms of the preexisting partnership agreement for securities in an operating company specifically identified at the time of the formation of the original partnership; (ii) A transaction in which the securities to be issued or exchanged are not required to be and are not registered under the Securities Act of 1933 (15 U.S.C. 77a (iii) A transaction that involves only issuers that are

official document · source cfr-2024

(Item 902) Individual partnership supplements.

CFR · 2024-01-01 · US · Title 17

(a) If two or more entities are proposed to be included in the roll-up transaction, provide the information specified in this Item (§ 229.902) in a separate supplement to the disclosure document for each entity. (b) The separate supplement required by paragraph (a) of this Item (§ 229.902) shall be filed as part of the registration statement, shall be delivered with the prospectus to investors in the partnership covered thereby, and shall include: (1) A statement in the forepart of the supplement to the effect that: (i) Supplements have been prepared for each partnership; (ii) The effects of the roll-up transaction may be different for investors in the various partnerships; and (iii) Upon receipt of a written request by an investor or his representative who has been so designated in writing, a copy of any supplement will be transmitted promptly, without charge, by the general partner or sponsor. (2) A brief description of each material risk and effect of the roll-up transaction, including, but not limited to, federal income tax consequences, for investors in the partnership, with appropriate cross references to the discussions of the risks, effects and tax consequences of the roll-up transaction required in the principal disclosure document pursuant to Items 904 and 915 of this subpart (§§ 229.904 and 229.915). Such discussion shall address the effect of the roll-up transaction on the partnership's financial condition and results of operations. (3) A statement concerning whet

official document · source cfr-2024

(Item 903) Summary.

CFR · 2024-01-01 · US · Title 17

(a) Provide in the forepart of the disclosure document a clear, concise and comprehensible summary of the roll-up transaction. (b) The summary required by paragraph (a) of this Item (§ 229.903) shall include a summary description of each of the following items, as well as any other material terms or consequences of the roll-up transaction necessary to an understanding of such transaction: (1) Each material risk and effect on investors, including, but not limited to: (i) Changes in the business plan, voting rights, cash distribution policies, form of ownership interest or management compensation; (ii) The general partner's conflicts of interest in connection with the roll-up transaction and in connection with the successor's future operations; and (iii) The likelihood that securities received by investors in the roll-up transaction will trade at prices substantially below the value assigned to such securities in the roll-up transaction and/or the value of the successor's assets; (2) The material terms of the roll-up transaction, including the valuation method used to allocate securities in the successor to investors in the partnerships; (3) Whether the general partner reasonably believes that the roll-up transaction is fair or unfair to investors in each partnership, including a brief discussion of the bases for such belief; (4) Any opinion from an outside party concerning the fairness of the roll-up transaction, including whether the opinion addresses the fairness of all poss

official document · source cfr-2024

(Item 904) Risk factors and other considerations.

CFR · 2024-01-01 · US · Title 17

(a) Immediately following the summary required by Item 903 of this subpart (§ 229.903), describe in reasonable detail each material risk and effect of the roll-up transaction on investors in each partnership, including, but not limited to: (1) The potential risks, adverse effects and benefits of the roll-up transaction for investors and for the general partner, including those which result from each matter described in response to Item 905 of this subpart (§ 229.905), with appropriate cross references to the comparative information required by Item 905; (2) The material risks arising from an investment in the successor; and (3) The likelihood that securities of the successor received by investors in the roll-up transaction will trade in the securities markets at a price substantially below the value assigned to such securities in the roll-up transaction and/or the value of the assets of the successor, and the effects on investors of such a trading market discount. (b) Quantify each risk or effect to the extent practicable. (c) State whether any of such risks or effects may be different for investors in any partnership and, if so, identify such partnership(s) and describe such difference(s).

official document · source cfr-2024

(Item 905) comparative information.

CFR · 2024-01-01 · US · Title 17

(a)(1) Describe the voting and other rights of investors in the successor under the successor's governing instruments and under applicable law. Compare such rights to the voting and other rights of investors in each partnership subject to the transaction under the partnerships' governing instruments and under applicable law. Describe the effects of the change(s) in such rights. (2) Describe the duties owed by the general partner of the successor to investors in the successor under the successor's governing instruments and under applicable law. Compare such duties to the duties owed by the general partner of each partnership to investors in the partnership under the partnership's governing instruments and under applicable law. Describe the effects of the change(s) in such duties. (b)(1) Describe each item of compensation (including reimbursement of expenses) payable by the successor after the roll-up transaction to the general partner and its affiliates or to any affiliate of the successor. Compare such compensation to the compensation currently payable to the general partner and its affiliates by each partnership. Describe the effects of the change(s) in compensation arrangements. (2) Describe each instance in which cash or other distributions may be made by the successor to the general partner and its affiliates or to any affiliate of the successor. Compare such distributions to the distributions currently paid or payable to the general partner and its affiliates by each par

official document · source cfr-2024

(Item 906) Allocation of roll-up consideration.

CFR · 2024-01-01 · US · Title 17

(a) Describe in reasonable detail the method used to allocate interests in the successor to investors in the partnerships and the reasons why such method was used. (b) Provide a table showing the calculation of the valuation of each partnership and the allocation of interests in the successor to investors. Such table shall include for each partnership the following information (or other information of a comparable character necessary to an understanding of the calculation and allocation): (1) The value assigned to each significant category of assets of the partnership and the total value assigned to the partnership; (2) The total value assigned to all partnerships; (3) The aggregate amount of interests in the successor to be allocated to each partnership and the percentage of the total amount of all such interests represented thereby; and (4) The amount of interests of the successor to be issued to investors per interest held in each partnership (on an equivalent interest basis, such as per $1,000 invested). (c) If interests in the successor will be allocated to the general partner in exchange for its general partner interest or otherwise or if the general partner will receive other consideration in connection with the roll-up transaction: (1) Describe in reasonable detail the method used to allocate interests in the successor to the general partner or to determine the amount of consideration payable to the general partner and the reasons such method(s) was used; and (2) Iden

official document · source cfr-2024

(Item 907) Background of the roll-up transaction.

CFR · 2024-01-01 · US · Title 17

(a)(1) Furnish a summary of the background of the transaction. Such summary shall include, but not be limited to, a description of any contacts, negotiations or transactions concerning any of the following matters: (i) A merger, consolidation, or combination of any of the partnerships; (ii) An acquisition of any of the partnerships or a material amount of any of their assets; (iii) A tender offer for or other acquisition of securities of any class issued by any of the partnerships; or (iv) A change in control of any of the partnerships. (2) The summary required by paragraph (a)(1) of this Item shall: (i) Cover the period beginning with each partnership's second full fiscal year preceding the date of the filing of the roll-up transaction; (ii) Include contacts, negotiations or transactions between the general partner or its affiliates and any person who would have a direct interest in the matters listed in paragraphs (a)(1)(i)-(iv) of this Item; and (iii) Identify the person who initiated such contacts, negotiations or transactions. (b) Briefly describe the background of each partnership, including, but not limited to: (1) The amount of capital raised from investors, the extent to which net proceeds from the original offering of interests have been invested, the extent to which funds have been invested as planned and the amount not yet invested; and (2) The partnership's investment objectives and the extent to which the partnership has achieved its investment objectives. (c) D

official document · source cfr-2024

(Item 908) Reasons for and alternatives to the roll-up transaction.

CFR · 2024-01-01 · US · Title 17

(a) Describe the reason(s) for the roll-up transaction. (b)(1) If the general partner or sponsor considered alternatives to the roll-up transaction being proposed, describe such alternative(s) and state the reason(s) for their rejection. (2) Whether or not described in response to paragraph (b)(1) of this Item (§ 229.908), describe in reasonable detail the potential alternative of continuation of the partnerships in accordance with their existing business plans, including the effects of such continuation and the material risks and benefits that likely would arise in connection therewith, and, if applicable, the general partner's reasons for not considering such alternative. (3) Whether or not described in response to paragraph (b)(1) of this Item (§ 229.908), describe in reasonable detail the potential alternative of liquidation of the partnerships, the procedures required to accomplish liquidation, the effects of liquidation, the material risks and benefits that likely would arise in connection with liquidation, and, if applicable, the general partner's reasons for not considering such alternative. (c) State the reasons for the structure of the roll-up transaction and for undertaking such transaction at this time. (d) State whether the general partner initiated the roll-up transaction and, if not, whether the general partner participated in the structuring of the transaction. (e) State whether the general partner recommends the roll-up transaction and briefly describe the re

official document · source cfr-2024

(Item 909) Conflicts of interest.

CFR · 2024-01-01 · US · Title 17

(a) Briefly describe the general partner's fiduciary duties to each partnership subject to the roll-up transaction and each actual or potential material conflict of interest between the general partner and the investors relating to the roll-up transaction. (b)(1) State whether or not the general partner has retained an unaffiliated representative to act on behalf of investors for purposes of negotiating the terms of the roll-up transaction. If no such representative has been retained, describe the reasons therefor and the risks arising from the absence of separate representation. (2) If an unaffiliated representative has been retained to represent investors: (i) Identify such unaffiliated representative; (ii) Briefly describe the representative's qualifications, including a brief description of any other transaction similar to the roll-up transaction in which the representative has served in a similar capacity within the past five years; (iii) Describe the method of selection of such representative, including a statement as to whether or not any investors were consulted in the selection of the representative and, if so, the names of such investors; (iv) Describe the scope and terms of the engagement of the representative, including, but not limited to, what party will be responsible for paying the (v) Describe any material relationship between the representative or its affiliates and: (A) The general partner, sponsor, any affiliate of the general partner or sponsor; or (B) An

official document · source cfr-2024

(Item 910) Fairness of the transaction.

CFR · 2024-01-01 · US · Title 17

(a) State whether the general partner reasonably believes that the roll-up transaction is fair or unfair to investors and the reasons for such belief. Such discussion must address the fairness of the roll-up transaction to investors in each of the partnerships and as a whole. If the roll-up transaction may be completed with a combination of partnerships consisting of less than all partnerships, or with portions of partnerships, the belief stated must address each possible combination. (b) Discuss in reasonable detail the material factors upon which the belief stated in paragraph (a) of this Item (§ 229.910) is based and, to the extent practicable, the weight assigned to each such factor. Such discussion should include an analysis of the extent, if any, to which such belief is based on the factors set forth in Instructions (2) and (3) to this Item (§ 229.910), paragraph (b)(1) of Item 909 of this subpart (§ 229.909(b)(1)) and Item 911 of this subpart (§ 229.911). This discussion also must: (1) Compare the value of the consideration to be received in the roll-up transaction to the value of the consideration that would be received pursuant to each of the alternatives discussed in response to Item 908(b) of this subpart (§ 229.908(b)); and (2) Describe any material differences among the partnerships (e.g., different types of assets or different investment objectives) relating to the fairness of the transaction. (c) If any offer of the type described in Instruction (2)(viii) to th

official document · source cfr-2024

(Item 911) Reports, opinions and appraisals.

CFR · 2024-01-01 · US · Title 17

(a)(1) (2) With respect to any report, opinion or appraisal described in paragraph (a)(1) of this Item (§ 229.911); (i) Identify such outside party; (ii) Briefly describe the qualifications of such outside party; (iii) Describe the method of selection of such outside party; (iv) Describe any material relationship between: (A) The outside party or its affiliates; and (B) The general partner, sponsor, the successor or any of their affiliates, (v) If such report, opinion or appraisal relates to the fairness of the consideration, state whether the general partner, sponsor or affiliate determined the amount of consideration to be paid or whether the outside party recommended the amount of consideration to be paid. (vi) Furnish a summary concerning such report, opinion or appraisal which shall include, but not be limited to, the procedures followed; the findings and recommendations; the bases for and methods of arriving at such findings and recommendations; instructions received from the general partner, sponsor or its affiliates; and any limitation imposed by the general partner, sponsor or affiliate on the scope of the investigation. If any limitation was imposed by the general partner, sponsor or affiliate on the scope of the investigation, including, but not limited to, access to its personnel, premises, and relevant books and records, state the reasons therefor. (vii) State whether any compensation paid to such outside party is contingent on the approval or completion of the r

official document · source cfr-2024

(Item 912) Source and amount of funds and transactional expenses.

CFR · 2024-01-01 · US · Title 17

(a) State the source and total amount of funds or other consideration to be used in the roll-up transaction. (b)(1) Furnish a reasonably itemized statement of all expenses incurred or estimated to be incurred in connection with the roll-up transaction including, but not limited to, filing fees, legal, financial advisory, accounting and appraisal fees, solicitation expenses and printing costs. Identify the persons responsible for paying any or all of such expenses. (2) State whether or not any partnership subject to the roll-up transaction will be, directly or indirectly, responsible for any or all of the expenses of the transaction. If any partnership will be so responsible, state the amount to be provided by each partnership and the sources of capital to finance such amount. (c) If all or any part of the consideration to be used by the sponsor or successor in the roll-up transaction is expected to be, directly or indirectly, provided by any partnership, state the amount to be provided by each partnership and the sources of capital to finance such amount. (d) If all or any part of the funds or other consideration is, or is expected to be, directly or indirectly borrowed by the sponsor or successor for the purpose of the roll-up transaction: (1) Provide a summary of each such loan agreement containing the identity of the parties, the term, the collateral, the stated and effective interest rates, and other material terms or conditions; and (2) Briefly describe any plans or arra

official document · source cfr-2024

(Item 913) Other provisions of the transaction.

CFR · 2024-01-01 · US · Title 17

(a) State whether or not appraisal rights are provided under applicable state law, under the partnership's governing instruments or will be voluntarily accorded by the successor, the general partner or the sponsor (or any of their affiliates) in connection with the roll-up transaction. If so, summarize such appraisal rights. If appraisal rights will not be available to investors (b) If any provision has been made to allow investors to obtain access to the books and records of the partnership or to obtain counsel or appraisal services at the expense of the successor, the general partner, the partnership, the sponsor (or any of their affiliates), describe such provision. (c) Discuss the investors' rights under federal and state law to obtain a partnership's list of investors.

official document · source cfr-2024

(Item 914) Pro forma financial statements: selected financial data.

CFR · 2024-01-01 · US · Title 17

(a) In addition to the information required by § 229.302 (Item 302 of Regulation S-K), for each partnership proposed to be included in a roll-up transaction provide: cash and cash equivalents, total assets at book value, total assets at the value assigned for purposes of the roll-up transaction (if applicable), total liabilities, general and limited partners' equity, net increase (decrease) in cash and cash equivalents, net cash provided by operating activities, distributions; and per unit data for net income (loss), book value, value assigned for purposes of the roll-up transaction (if applicable), and distributions (separately identifying distributions that represent a return of capital). This information must be provided for the previous two fiscal years. Additional or other information must be provided if material to an understanding of each partnership proposed to be included in a roll-up transaction. (b) Provide pro forma financial information (including oil and gas reserves and cash flow disclosure, if appropriate), assuming: (1) All partnerships participate in the roll-up transaction; and (2) Participation in a roll-up transaction of those partnerships that on a combined basis have the lowest combined net cash provided by operating activities for the last fiscal year of such partnerships, (c) The pro forma financial statements required by paragraph (b) of this Item (§ 229.914) shall disclose the effect of the roll-up transaction on the successor's: (1) Balance sheet a

official document · source cfr-2024

(Item 915) Federal income tax consequences.

CFR · 2024-01-01 · US · Title 17

(a) Provide a brief, clear and understandable summary of the material Federal income tax consequences of the roll-up transaction and an investment in the successor. Where a tax opinion has been provided, briefly summarize the substance of such opinion, including identification of the material consequences upon which counsel has not been asked, or is unable, to opine. If any of the material Federal income tax consequences are not expected to be the same for investors in all partnerships, the differences shall be described. (b) State whether or not the opinion of counsel is included as an appendix to

official document · source cfr-2024

(Kind) burgers; (Kind) patties.

CFR · 2024-01-01 · US · Title 9

Such product consists of 100 percent poultry of the kind indicated, with skin and fat not in excess of natural proportions. Product containing fillers or binders shall be named “(Kind) Patties.”

official document · source cfr-2024

(N Group).

CFR · 2024-01-01 · US · Title 7

Extremely common tobacco which does not meet the minimum specifications or which exceeds the tolerance of the lowest grade of any other group except scrap.

official document · source cfr-2024

(Rule 15fh-4) Antifraud provisions for security-based swap dealers and major security-based swap participants; special requirements for security-based swap dealers acting as advisors to special entities.

CFR · 2024-01-01 · US · Title 17

(a) (1) To employ any device, scheme, or artifice to defraud any special entity or prospective customer who is a special entity; (2) To engage in any transaction, practice, or course of business that operates as a fraud or deceit on any special entity or prospective customer who is a special entity; or (3) To engage in any act, practice, or course of business that is fraudulent, deceptive, or manipulative. (b) (1) (2) (i) The authority of the special entity to enter into a security-based swap; (ii) The financial status of the special entity, as well as future funding needs; (iii) The tax status of the special entity; (iv) The hedging, investment, financing or other objectives of the special entity; (v) The experience of the special entity with respect to entering into security-based swaps, generally, and security-based swaps of the type and complexity being recommended; (vi) Whether the special entity has the financial capability to withstand changes in market conditions during the term of the security-based swap; and (vii) Such other information as is relevant to the particular facts and circumstances of the special entity, market conditions and the type of security-based swap or trading strategy involving a security-based swap being recommended. (3) (i) The transaction is executed on a registered or exempt security-based swap execution facility or registered national securities exchange; and (ii) The security-based swap dealer does not know the identity of the counterparty

official document · source cfr-2024

(Substituted-dialkyl(C=1~7)silyl)alkanenitrile (generic).

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (iv) (b) (1) (2) (3)

official document · source cfr-2024

(Z)-7,8-epoxy-2-methyloctadecane (Disparlure); exemption from the requirement of a tolerance.

CFR · 2024-01-01 · US · Title 40

An exemption from the requirement of a tolerance is established for residues of (Z)-7,8-epoxy-2-methyloctadecane on all food and feed crops that occur when it is used to treat trees, shrubs, and pastures and such use results in unintentional spray and drift to non-target vegetation including non-food, food, and feed crops. This active ingredient is also known as Disparlure.

official document · source cfr-2024

1

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (A) If as a result of the test data required under the section 5(e) consent order for these substances, the employer becomes aware that these substances may present a risk of injury to the environment, the employer must incorporate this new information, and any information on methods for protecting against such risk, into a SDS as described in § 721.72(c) within 90 days (B) The employer must ensure that persons who will receive, or who have received these substances from the employer within 5 years from the date the employer becomes aware of the new information described in paragraph (a)(2)(i)(A) of this section, are provided an SDS as described in § 721.72(c) containing the information required under paragraph (a)(2)(i)(A) of this section within 90 days from the time the employer becomes aware of the new information. (ii) (b) (1) (2)

official document · source cfr-2024

1

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2)

official document · source cfr-2024

1

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (iv) (v) (b) (1) (2) (3)

official document · source cfr-2024

1, 9-Cyclohexadecadiene.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2)

official document · source cfr-2024

1,1′-Biphenyl, 3,3′,4,4′-tetramethyl-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2,3-Propanetricarboxamide, N1,N2,N3-tris(2-methylcyclohexyl)-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2,3-Propanetriol, homopolymer, alkanoates (generic) and Glycerides, alkanoate, mono-, di- and tri- (generic).

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2) (3)

official document · source cfr-2024

1,2,3-Propanetriol, homopolymer, dodecanoate.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2,4,5,7,8-Hexoxonane, 3,6,9-triethyl-3,6,9-trimethyl-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (iv) (b) (1) (2)

official document · source cfr-2024

1,2,4,5,7,8-Hexoxonane, 3,6,9-trimethyl-, 3,6,9-tris(alkyl) derivs. (generic).

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (iv) (b) (1) (2)

official document · source cfr-2024

1,2,4,5-Tetrachlorobenzene.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new use is: Manufacture, import, or processing of 10,000 pounds or more per year per facility for any use. (b) (1) (2) [Reserved]

official document · source cfr-2024

1,2,4-Benzenetricarboxylic acid, 1,2,4-trinonyl ester.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (b) (1) (2)

official document · source cfr-2024

1,2,4-Benzenetricarboxylic acid, mixed decyl and octyl triesters.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (A) If as a result of the test data required under the TSCA section 5(e) consent order for the substance, the employer becomes aware that the substance may present a risk of injury to human health or the environment, the employer must incorporate this new information, and any information on methods for protecting against such risk, into a SDS as described in § 721.72(c) within 90 days from the time the employer becomes aware of the new information. If the substance is not being manufactured, processed, or used in the employer's workplace, the employer must add the new information to a SDS before the substance is reintroduced into the workplace. (B) The employer must ensure that persons who will receive the PMN substance from the employer, or who have received the PMN substance from the employer within 5 years from the date the employer becomes aware of the new information described in paragraph (a)(2)(iii)(A) of this section, are provided an SDS containing the information required under paragraph (a)(2)(iii)(A) of this section within 90 days from the time the employer becomes aware of the new information. (b) (1) (2)

official document · source cfr-2024

1,2,4-Benzenetricarboxylic acid, tris [4-(ethenyloxy) butyl] ester.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Benzenediamine, 4-ethoxy, sulfate.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new use is: Manufacture, import, or processing in powder or dry solid form. (b) [Reserved]

official document · source cfr-2024

1,2-Benzenedicarboxylic acid, 1,2-bis(methylcyclohexyl) ester.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Benzenedicarboxylic acid, di-C

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Benzenedicarboxylic acid, di-C

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Benzenedicarboxylic acid, mixed esters with benzyl alc., cyclohexanol, 2-ethyl-1-hexanol, fumaric acid and propylene glycol.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Cyclohexanedi carboxylic acid, 1-(2-phenylhydrazide).

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Cyclohexanedi carboxylic acid, 1-(phenylmethyl) ester, ester with 2,2,4-trimethyl-1,3-pentanediol mono(2-methylpropanoate).

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2) (3)

official document · source cfr-2024

1,2-Cyclohexanedicarboxylic acid, 1-(2-ethylhexyl) 2-(2-methylpropyl) ester.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Cyclohexanedicarboxylic acid, 1-butyl 2-(phenylmethyl) ester.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Cyclohexanedicarboxylic acid, 2,2-bis[[[[2-[(oxiranylmethoxy) carbonyl]cyclohexy]carbonyl] oxy]methyl]-1,3-propanediyl bis(oxiranylmethyl) ester.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) Industrial, commercial, and consumer activities. Requirements as specified in § 721.80(q). (b) (1) (2) (3)

official document · source cfr-2024

1,2-Cyclohexanedicarboxylic acid, benzyl C8-10-isoalkyl esters, C9-rich.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2)

official document · source cfr-2024

1,2-Cyclohexanedicarboxylic acid, benzyl nonyl ester, branched and linear.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2)

official document · source cfr-2024

1,2-Ethanediol bis(4-methylbenzenesulfonate); 2,2-oxybis-ethane bis(4-methylbenzenesulfonate); ethanol, 2,2′-[oxybis(2,1-ethanediyl oxy)]bis-, bis(4-methylbenzenesulfonate); ethanol, 2,2′-[oxybis (2,1-ethane diyloxy)] bis-, bis(4-methylbenzenesulfonate); ethanol, 2,2′-[[1-[(2-propenyloxy) methyl]-1,

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Ethanediol, 1,2-dibenzoate.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (iv) (b) (1) (2)

official document · source cfr-2024

1,2-Ethanediol, 1-carbamate.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Ethanediol, reaction products with epichlorohydrin.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Propanediol, 3-(2-propenyloxy)-, bis(4-methylbenzene sulfonate); 2-propanol, 1-[2-[[(4-methylphenyl)sulfonyl] oxy]ethoxy]-3-(2-propenyloxy)-4-methylbenzenesulfonate; and 2-propanol, 1-[2-[2-[[(4-methylphenyl)sulfonyl]oxy] ethoxy]ethoxy]-3-(2-propenyloxy)-, 4-methylbenzenesulfonate.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-Propanediol, 3-(diethylamino)-, polymers with 5-isocyanato-1- (isocyanatomethyl)-1,3,3-trimethylcyclohexane, propylene glycol and reduced Me esters of reduced polymd. oxidized tetrafluoroethylene, 2-ethyl-1-hexanol-blocked, acetates (salts).

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,2-dibromo-3-chloropropane.

CFR · 2024-01-01 · US · Title 29

(a) (2) This section does not apply to: (i) Exposure to DBCP which results solely from the application and use of DBCP as a pesticide; or (ii) The storage, transportation, distribution or sale of DBCP in intact containers sealed in such a manner as to prevent exposure to DBCP vapors or liquid, except for the requirements of paragraphs (i), (n) and (o) of this section. (b) (c) (2) (d) [Reserved] (e) (2) The employer shall limit access to regulated areas to authorized persons. (f) (ii) For the purposes of this paragraph, employee exposure is that exposure which would occur if the employee were not using a respirator. (2) (3) (ii) If the monitoring required by this section reveals employee exposures to be in excess of the permissible exposure limit, the employer must repeat these measurements for each such employee at least quarterly. The employer must continue quarterly monitoring until at least two consecutive measurements, taken at least seven (7) days apart, are at or below the permissible exposure limit. Thereafter the employer must monitor at least every 6 months. (4) (5) (ii) Whenever the results indicate that employee exposure exceeds the permissible exposure limit, the employer shall include in the written notice a statement that the permissible exposure limit was exceeded and a description of the corrective action being taken to reduce exposure to or below the permissible exposure limit. (6) (g) (2) (ii) The written program shall include a detailed schedule for develop

official document · source cfr-2024

1,2-dibromo-3-chloropropane.

CFR · 2024-01-01 · US · Title 29

The publisher provides no abstract for this document; none is invented here.

official document · source cfr-2024

1,2-dibromo-3-chloropropane.

CFR · 2024-01-01 · US · Title 29

The publisher provides no abstract for this document; none is invented here.

official document · source cfr-2024

1,3 Dioxolane-4-butanol, 2-ethenyl-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2) (3)

official document · source cfr-2024

1,3,5-Naphthalenetrisulfonic acid.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (b) (1) (2) (3)

official document · source cfr-2024

1,3,5-Triazine, 2,4,6-trichloro-, polymer with piperazine, reaction products with morpholine.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2) (3)

official document · source cfr-2024

1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris[3-(2-oxiranyl)propyl]-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2)

official document · source cfr-2024

1,3,5-Triazine-2,4-diamine,   6-phenyl-, reaction products with polyalkylene glycol mono- alkyl ether and 2,4-toluene diisocyanate (generic).

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2) (3)

official document · source cfr-2024

1,3,5-Trinitrobenzene.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new use is: Manufacture, import, or processing of 10,000 pounds or more per year per facility for any use. (b) (1) (2) [Reserved]

official document · source cfr-2024

1,3,6-Naphthalenetrisulfonic acid, 7-[[2-[(aminocarbonyl)amino]- 4-[[4-[[2-[2-(ethenylsulfonyl)ethoxy] ethyl]amino]- 6-fluoro-1,3,5-triazin-2-yl]amino]phenyl]azo], trisodium salt.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,3-Benzenediamine, 4-(1,1-di­methylethyl)-ar-methyl.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) Use other than for applications where the substance will be completely reacted (cured or used as a chemical intermediate). (ii) Any method of disposal other than by landfill, incineration, or for wastewater from vent scrubbers, steam vacuum ejectors, pad washings, equipment washouts, and stormwater runoffs, wastewater treatment in permitted industrial wastewater treatment facilities. Each method of disposal must meet all applicable local, State, and Federal laws and regulations. (iii) Any manner or method of manufacturing, importing, or processing without establishing a program whereby: (A) Any person who may be exposed dermally to the substance wears: ( ( ( (B) Any person who may be exposed to the substance through inhalation during manufacture, in addition to the dermal protective equipment described in paragraph (a)(2)(iii)(A) of this section, wears at a minimum, a National Institute for Occupational Safety and Health approved, category 23C respirator, organic vapor type. Use of the respirator must be according to 29 CFR 1910.134 and 30 CFR part 11. If a full-face type respirator is selected and worn, the chemical safety goggles requirement in paragraph (a)(2)(iii)(A)( (C)( ( (D) All persons that receive the PMN substance are notified by means of a Safety Data Sheet (“SDS”) which includes, at a minimum, the language specified in paragraph (a)(2)(iii)(C)( (E) Each container of the substance distributed in commerce has affixed to it

official document · source cfr-2024

1,3-Benzenedicarboxylic acid, bis[[4-[(ethenyloxy)methyl] cyclohexyl] methyl] ester.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,3-Benzenedicarboxylic acid, polymer with 2,2-dimethyl-1,3-propanediol, 1,2-ethanediol, 2-ethyl-2-(hydroxymethyl)-1,3-propanediol, hexanedioic acid, 1,6-hexanediol and 1,3-isobenzofurandione, N-[[1,3,3-trimethyl-5-[[[2-[(1-oxo-2- propen-1-yl)oxy]ethoxy]carbonyl]amino]cyclohexyl]methyl]carbamate N-[

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (iii) (b) (1) (2)

official document · source cfr-2024

1,3-Benzenedicarboxylic acid, polymer with 3-methyl-1,5-pentanediol.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2) (3)

official document · source cfr-2024

1,3-Benzenedimethanamine, N-(2-phenylethyl) derivs.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,3-Benzenedimethanamine, polymers with epichlorohydrin-polyethylene glycol reaction products.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,3-Benzenediol, 4-[1-[[3-(lH-imidazol-1-yl)propyl]imino] ethyl]-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,3-Benzenediol, polymer with 1,1'-methylenebis[isocyanatobenzene].

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) (b) (1) (2) (3)

official document · source cfr-2024

1,3-Butadiene.

CFR · 2024-01-01 · US · Title 29

(a) (2)(i) Except for the recordkeeping provisions in paragraph (m)(1) of this section, this section does not apply to the processing, use, or handling of products containing BD or to other work operations and streams in which BD is present where objective data are reasonably relied upon that demonstrate the work operation or the product or the group of products or operations to which it belongs may not reasonably be foreseen to release BD in airborne concentrations at or above the action level or in excess of the STEL under the expected conditions of processing, use, or handling that will cause the greatest possible release or in any plausible accident. (ii) This section also does not apply to work operations, products or streams where the only exposure to BD is from liquid mixtures containing 0.1% or less of BD by volume or the vapors (iii) Except for labeling requirements and requirements for emergency response, this section does not apply to the storage, transportation, distribution or sale of BD or liquid mixtures in intact containers or in transportation pipelines sealed in such a manner as to fully contain BD vapors or liquid. (3) Where products or processes containing BD are exempted under paragraph (a)(2) of this section, the employer shall maintain records of the objective data supporting that exemption and the basis for the employer's reliance on the data, as provided in paragraph (m)(1) of this section. (b) (c) (2) (d) (ii) Representative 8-hour TWA employee expos

official document · source cfr-2024

1,3-Butanediol, (3R)-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024

1,3-Butanediol, 3-methyl-.

CFR · 2024-01-01 · US · Title 40

(a) (2) The significant new uses are: (i) (ii) [Reserved] (b) (1) (2)

official document · source cfr-2024